Clinical Trial Update: Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease [Phase 1, Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 1/2 study evaluating Visilizumab for the treatment of acute graft-versus-host disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Visilizumab (visilizumab)

Snippet

Sponsor: Facet Biotech | Conditions: Graft vs Host Disease | Phase 1, Phase 2 | Status: COMPLETED